Literature DB >> 8642283

B7-CD28 costimulation unveils the hierarchy of tumor epitopes recognized by major histocompatibility complex class I-restricted CD8+ cytolytic T lymphocytes.

J V Johnston1, A R Malacko, M T Mizuno, P McGowan, I Hellström, K E Hellström, H Marquardt, L Chen.   

Abstract

Immunization of mice with tumors genetically engineered to express the B7 costimulatory molecules amplifies the antitumor immune response mediated by CD8+ cytolytic T lymphocytes (CTL). In this report, we examined the effect of B7-CD28 costimulation on the hierarchy of tumor epitopes. Using a combination of affinity chromatography/reversed-phase high performance liquid chromatography and CTL cloning, we show that major histocompatibility complex (MHC) class I molecules from EL4 lymphoma cells can present at least six distinct CTL epitopes presented by MHC class I molecules. Nevertheless, mice immunized with wild-type B7-negative EL4 cells develop CTL only to one immunodominant epitope. In contrast, immunization with B7-transduced EL4 cells led to not only the amplification of the CTL response to this immunodominant epitope, but also to the recognition of five otherwise silent subdominant epitopes. The adoptive transfer of a CTL clone against such a subdominant epitope cured mice bearing EL4 lymphoma growing as an ascites tumor. The fact that CTL response can be spread to normally silent epitopes as a result of B7-CD28 costimulation suggests a novel approach to manipulate the hierarchy of CTL epitopes and offers an opportunity to explore novel targets for T cell-mediated cancer therapy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8642283      PMCID: PMC2192349          DOI: 10.1084/jem.183.3.791

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  37 in total

Review 1.  Dominance and crypticity of T cell antigenic determinants.

Authors:  E E Sercarz; P V Lehmann; A Ametani; G Benichou; A Miller; K Moudgil
Journal:  Annu Rev Immunol       Date:  1993       Impact factor: 28.527

Review 2.  The role of the CD28 receptor during T cell responses to antigen.

Authors:  P S Linsley; J A Ledbetter
Journal:  Annu Rev Immunol       Date:  1993       Impact factor: 28.527

3.  Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation.

Authors:  C D Gimmi; G J Freeman; J G Gribben; G Gray; L M Nadler
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-15       Impact factor: 11.205

4.  A nonimmunodominant nucleoprotein-derived peptide is presented by influenza A virus-infected H-2b cells.

Authors:  M Oukka; N Riché; K Kosmatopoulos
Journal:  J Immunol       Date:  1994-05-15       Impact factor: 5.422

5.  Tumors with reduced expression of a cytotoxic T lymphocyte recognized antigen lack immunogenicity but retain sensitivity to lysis by cytotoxic T lymphocytes.

Authors:  H Koeppen; M Acena; A Drolet; D A Rowley; H Schreiber
Journal:  Eur J Immunol       Date:  1993-11       Impact factor: 5.532

Review 6.  Costimulation of T cells for tumor immunity.

Authors:  L Chen; P S Linsley; K E Hellström
Journal:  Immunol Today       Date:  1993-10

7.  In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53.

Authors:  J G Houbiers; H W Nijman; S H van der Burg; J W Drijfhout; P Kenemans; C J van de Velde; A Brand; F Momburg; W M Kast; C J Melief
Journal:  Eur J Immunol       Date:  1993-09       Impact factor: 5.532

8.  Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma.

Authors:  Y Li; P McGowan; I Hellström; K E Hellström; L Chen
Journal:  J Immunol       Date:  1994-07-01       Impact factor: 5.422

9.  Production of interleukin-2 by EL4 tumor cells induces natural killer cell- and T-cell-mediated immunity.

Authors:  M J Visseren; M Koot; E I van der Voort; L A Gravestein; H J Schoenmakers; W M Kast; M Zijlstra; C J Melief
Journal:  J Immunother Emphasis Tumor Immunol       Date:  1994-02

10.  Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity.

Authors:  L Chen; P McGowan; S Ashe; J Johnston; Y Li; I Hellström; K E Hellström
Journal:  J Exp Med       Date:  1994-02-01       Impact factor: 14.307

View more
  16 in total

Review 1.  Vaccination strategies for lymphomas.

Authors:  Mohammed M Dar; Larry W Kwak
Journal:  Curr Oncol Rep       Date:  2003-09       Impact factor: 5.075

2.  Generation of CD8+ T cells specific for transporter associated with antigen processing deficient cells.

Authors:  E Z Wolpert; M Petersson; B J Chambers; J K Sandberg; R Kiessling; H G Ljunggren; K Kärre
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-14       Impact factor: 11.205

Review 3.  The many sounds of T lymphocyte silence.

Authors:  Ignacio Melero; Ainhoa Arina; Lieping Chen
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

Review 4.  Lung cancer immunotherapy.

Authors:  Luis E Raez; Steven Fein; Eckhard R Podack
Journal:  Clin Med Res       Date:  2005-11

5.  B7-CTLA4 interaction enhances both production of antitumor cytotoxic T lymphocytes and resistance to tumor challenge.

Authors:  P Zheng; Y Wu; Y Guo; C Lee; Y Liu
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

Review 6.  Specific immunotherapy of cancer in elderly patients.

Authors:  S Matzku; M Zöller
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

7.  Role of CD28/CD80-86 and CD40/CD154 costimulatory interactions in host defense to primary herpes simplex virus infection.

Authors:  K H Edelmann; C B Wilson
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

8.  B7-H1 maintains the polyclonal T cell response by protecting dendritic cells from cytotoxic T lymphocyte destruction.

Authors:  Ling Chen; Takeshi Azuma; Weiwei Yu; Xu Zheng; Liqun Luo; Lieping Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2018-03-05       Impact factor: 11.205

9.  Priming of immune responses against transporter associated with antigen processing (TAP)-deficient tumours: tumour direct priming.

Authors:  Xiao-Lin Li; Dongqing Zhang; David Knight; Yoshinobu Odaka; Jonathan Glass; J Michael Mathis; Qian-Jin Zhang
Journal:  Immunology       Date:  2009-11       Impact factor: 7.397

10.  Effect of B7.1 costimulation on T-cell based immunity against TAP-negative cancer can be facilitated by TAP1 expression.

Authors:  Xiao-Lin Li; Yong-Yu Liu; David Knight; Yoshinobu Odaka; J Michael Mathis; Runhua Shi; Jonathan Glass; Qian-Jin Zhang
Journal:  PLoS One       Date:  2009-07-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.